Asciminib China listing status and official approval information

Asciminib (Asciminib) is a new type of targeted drug, mainly used for the treatment of chronic myelogenous leukemia (CML), especially for patients who are resistant or intolerant to first-line treatments such as imatinib. According to the latest information, asinib has been officially approved for marketing in China, providing a new treatment option for domestic CML patients. This marks China's further integration with international standards in the field of precision targeted therapy.

In the domestic market, although Asnibu has been launched, it has not yet been included in the medical insurance system. This means that patients need to pay for themselves when purchasing. The specific price varies by region and hospital. It is recommended that patients consult the local hospital pharmacy to obtain an accurate quote before purchasing. Despite its higher price, asinib provides significant clinical benefit for some patients who are resistant to traditional TKIs.

In overseas markets, Asnib also has two options: original drugs and generic drugs. The original drugs are mainly European versions, which are expensive and may reach tens of thousands of yuan per box, posing a heavy financial burden to patients who take the drugs for a long time. In contrast, the price of generic drugs in Laos is only about more than 4,000 yuan, and the ingredients of the drugs are basically the same as the original drugs, providing patients with a more economical choice.

It should be noted that as a targeted drug, asthnib should strictly follow the doctor's instructions during the medication period, monitor blood and tumor indicators regularly, and avoid adjusting the dosage or stopping the medication on your own. At the same time, since it has not yet been included in medical insurance, patients need to evaluate their financial affordability in advance and choose a medication plan that suits them based on the doctor's advice to ensure treatment effectiveness and safety.

Reference materials:https://www.drugs.com/